Search Result

Results for "

alpha helix

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (1) Bacterial (4) Bcl-2 Family (1) Biochemical Assay Reagents (1) c-Myc (1) Cholinesterase (ChE) (1) DNA/RNA Synthesis (1) Enteropeptidase (1) ERK (1) Exosomes (1) HIV (1) HIV Protease (1) Liposome (5) Orexin Receptor (OX Receptor) (1) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (1) Phospholipase (1) PKA (1) Potassium Channel (2) Prion Protein (1) Ras (1) Renin (1) SARS-CoV (2) SGLT (1) Sigma Receptor (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (3) Infection (9) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (2)

By Targets:

Amino Acid Derivatives (2)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (1)

Bacterial (4)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

c-Myc (1)

Cholinesterase (ChE) (1)

DNA/RNA Synthesis (1)

Enteropeptidase (1)

ERK (1)

Exosomes (1)

HIV (1)

HIV Protease (1)

Liposome (5)

Orexin Receptor (OX Receptor) (1)

Peptide-Drug Conjugates (PDCs) (1)

Phosphatase (1)

Phospholipase (1)

PKA (1)

Potassium Channel (2)

Prion Protein (1)

Ras (1)

Renin (1)

SARS-CoV (2)

SGLT (1)

Sigma Receptor (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (3)

Infection (9)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Antibodies

Targets Recommended: 5 alpha Reductase IFNAR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114855

BT2 5+ Cited Publications	Bcl-2 Family	Metabolic Disease
BT2 is a BCKDC kinase (BDK) inhibitor with an IC₅₀ of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC) . BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a K_i value of 59 μM .

HY-P5423

GALA	Exosomes Liposome	Cancer
GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. GALA significantly promotes the cytosolic release of cargos carried by exosomes, plasmids and liposomes, effectively enhances gene transfection efficiency, and drives gene knockdown of functional macromolecules (such as siRNA) in alveolar epithelial cells (with no significant cytotoxicity at effective concentrations). GALA serves as a critical tool for studies on lung cancer metastasis (e.g., melanoma lung metastasis) and lung-targeted drug delivery systems .

HY-P0311

LAH4	Bacterial	Infection
LAH4, an alpha-helix of the designed amphipathic peptide antibiotic, exhibits potent antimicrobial, nucleic acid transfection and cell penetration activities. LAH4 possesses high plasmid DNA delivery capacities. LAH4 has a strong affinity for anionic lipids found in the outer membrane of bacterial membranes .

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	DNA/RNA Synthesis	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .

HY-P0311A

LAH4 TFA	Bacterial	Infection
LAH4 TFA, an alpha-helix of the designed amphipathic peptide antibiotic, exhibits potent antimicrobial, nucleic acid transfection and cell penetration activities. LAH4 TFA possesses high plasmid DNA delivery capacities. LAH4 TFA has a strong affinity for anionic lipids found in the outer membrane of bacterial membranes .

HY-W006886

Fmoc-(R)-2-(7-octenyl)Ala-OH	Amino Acid Derivatives	Others
Fmoc-(R)-2-(7-octenyl) Ala-OH is an unnatural Fmoc-protected amino acid and modification module. Fmoc-(R)-2-(7-octenyl) Ala-OH serves as a key building block for all-hydrocarbon cross-linking modification of antimicrobial peptides, and facilitates the generation of stapled peptide derivatives. When introduced into specific sites of the parent peptide, Fmoc-(R)-2-(7-octenyl) Ala-OH effectively increases the *α-helix* content of the peptide chain, thereby significantly enhancing its antimicrobial activity and proteolytic stability. Fmoc-(R)-2-(7-octenyl) Ala-OH is widely used in research on bacterial infections and the development of related antimicrobial agents . Stapled peptide is a specially chemically modified polypeptide. It locks the peptide chain into a stable α-helical structure by introducing a "staple"-like chemical bridge (usually an all-carbon backbone) at specific positions of the peptide chain.

HY-P1341

OXA(17-33) Orexin A (17-33) (human, mouse, rat, bovine)	Orexin Receptor (OX Receptor) Sigma Receptor Phospholipase	Neurological Disease
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC₅₀=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca ²⁺ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .

HY-75129

Pyridin-3-ylboronic acid	Biochemical Assay Reagents	Others
Pyridin-3-ylboronic acid is an organic compound. Pyridin-3-ylboronic acid is a key reagent in the Suzuki-Miyaura cross-coupling reaction. Pyridin-3-ylboronic acid is used in organic synthesis to construct oligopyridine compounds, and then as an α-helix mimetic to study protein-protein interactions .

HY-P4118

EB1 peptide Penetrating analog	Amino Acid Derivatives Peptide-Drug Conjugates (PDCs)	Others
EB1 peptide (Penetrating analog) is an endosomolytic agent and siRNA delivery agent. EB1 peptide forms an amphipathic alpha helix upon protonation in early-late endosomes, drives endosomal membrane permeabilization, and enables endocytosed siRNA escape into the cytosol. EB1 peptide facilitates biologically active siRNA cellular uptake and targeted gene silencing. EB1 peptide forms complexes with siRNA. EB1 peptide can be used for drug delivery research .

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

HY-P5917A

Vm24-toxin TFA Vaejovis mexicanus peptide 24 TFA	Potassium Channel	Inflammation/Immunology Cancer
Vm24-toxin (Vaejovis mexicanus peptide 24) TFA, a 36-residue peptide, is a potent and selective Kv1.3 blocker with a K_d of ~3 pM in lymphocytes. Vm24-toxin TFA shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin TFA folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin TFA attenuates the CD4 ⁺ effector memory T cell response to T cell receptor (TCR) stimulation .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

HY-150536

EP39	HIV HIV Protease	Infection
EP39 is a potent HIV-1 maturation inhibitor. EP39 interacts with the SP1 domain of Gag. EP39 decreases the dynamics of CA-SP1 junction, by binding to the QVT motif of the SP1 domain, and perturbs the natural coil-helix equilibrium on both sides of the SP1 domain by stabilizing the transient alpha helical structure. EP39 acts by arresting maturation of HIV-1 thereby blocking its infectivity .

HY-P3916

GVLSNVIGYLKKLGTGALNAVLKQ	Bacterial	Infection Inflammation/Immunology
GVLSNVIGYLKKLGTGALNAVLKQ is an antimicrobial peptide with 24-amino acid. GVLSNVIGYLKKLGTGALNAVLKQ can potentially form α-helix. GVLSNVIGYLKKLGTGALNAVLKQ (PGQ) has activity against Gram-negative, Gram-positive bacteria and the yeast Candida albicans .

HY-P5827

SBP1 peptide	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SBP1 peptide is a chemically synthesized 23-mer peptide fragment of the ACE2 PD α1 helix. SBP1 peptide associates with micromolar affinity to insect-derived SARS-CoV-2-RBD protein .

HY-P10534

ccβ	Prion Protein	Infection Neurological Disease
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .

HY-168886

Anticancer agent 263	c-Myc	Cancer
Anticancer agent 263 (compound 7) is a potent anticancer agent. Anticancer agent 263 binds to the G-quadruplex DNA (G4) sequence 22-mer Pu22, a mimic of c-Myc DNA. Anticancer agent 263 is a structure modulator, showcasing a significant enhancement in protein α-helix formation and the capability to form supramolecular network. Anticancer agent 263 shows no cytotoxicity .

HY-P5917

Vm24-toxin Vaejovis mexicanus peptide 24	Potassium Channel	Inflammation/Immunology Cancer
Vm24-toxin (Vaejovis mexicanus peptide 24), a 36-residue peptide, is a potent and selective Kv1.3 blocker with a K_d of ~3 pM in lymphocytes. Vm24-toxin shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin attenuates the CD4 ⁺ effector memory T cell response to T cell receptor (TCR) stimulation .

HY-169173

AL284	Cholinesterase (ChE)	Infection
AL284 is a potent anopheles gambiae acetylcholinesterase 1 (AgAChE1) inhibitor. AL284 interactions with Tyr489Ag in the α-helix next to loop 2, and Trp441Ag at the top of the gorge. AL284 has the potential for the research of disease-transmitting mosquitoes .

HY-P11630

ZM-804	Bacterial	Cardiovascular Disease Infection
ZM-804 is a cationic α-helix antimicrobial peptide. ZM-804 targets bacterial cell membranes. ZM-804 demonstrates antimicrobial activity and prevents the infection of tomato plants by Pst DC3000. ZM-804 inhibits the growth of B. subtilis and E. coli (the same MICs of 41.10 μg/mL). ZM-804 exhibits low hemolytic activity .

HY-180201

SGLT2-IN-4	SGLT	Metabolic Disease
SGLT2-IN-4 (Compound 1) is a selective and orally active sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor. SGLT2-IN-4 can increase the proportion of protein α-helix and enhance the stability of the SGLT2-D201A mutant. SGLT2-IN-4 can be used for the research of type 2 diabetes .

HY-182098C

DSPE-PEG5000-GALA	Liposome	Cancer
DSPE-PEG5000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG5000-GALA can be used for drug delivery .

HY-182098

DSPE-PEG1000-GALA	Liposome	Cancer
DSPE-PEG1000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG1000-GALA can be used for drug delivery .

HY-182098A

DSPE-PEG2000-GALA	Liposome	Cancer
DSPE-PEG2000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG2000-GALA can be used for drug delivery .

HY-182098B

DSPE-PEG3400-GALA	Liposome	Cancer
DSPE-PEG3400-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG3400-GALA can be used for drug delivery .

HY-181420A

BBO-11818	Ras Phosphatase ERK Apoptosis	Cancer
BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC₅₀=28-120 nM). BBO-11818 specifically binds to the *Switch-II/Helix* 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1 antibody or PI3Kα** inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer .

HY-P1609

CP-69799	Renin Enteropeptidase	Cardiovascular Disease
CP-69799 is an azahomostatine-containing oligopeptide transition-state analogue inhibitor with a hog renin IC₅₀ of 6e-9 M, human plasma renin IC₅₀ of 3e-7 M and K_i of 0.310 μM, and endothiapepsin K_i of 0.27 μM. CP-69799 binds endothiapepsin’s active site cleft in extended conformation, fills S4 to S3' pockets, displaces native solvent molecules, induces domain rotation, and reduces thermal mobility of endothiapepsin’s flap and helix regions. CP-69799 acts as a transition-state analogue inhibitor of hog renin and human plasma renin. CP-69799 contains a polar lysine residue at the P2' position, with a nitrogen atom replacing the P1' Cα atom of the hydroxyethylene dipeptide isostere. CP-69799 can be used for the research of hypertension .

Cat. No.	Product Name

HY-L033

Peptidomimetic Library	370 compounds
Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery. MCE Peptidomimetic Library contains 370 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.

Peptidomimetic Library

370 compounds

Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery.

MCE Peptidomimetic Library contains 370 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.

HY-L0119V

Asinex PPI Pre-Plated Library	3,253 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.

Asinex PPI Pre-Plated Library

3,253 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.

Cat. No.	Product Name	Type

HY-75129

Pyridin-3-ylboronic acid	Biochemical Assay Reagents
Pyridin-3-ylboronic acid is an organic compound. Pyridin-3-ylboronic acid is a key reagent in the Suzuki-Miyaura cross-coupling reaction. Pyridin-3-ylboronic acid is used in organic synthesis to construct oligopyridine compounds, and then as an α-helix mimetic to study protein-protein interactions .

HY-182098C

DSPE-PEG5000-GALA	Biochemical Assay Reagents
DSPE-PEG5000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG5000-GALA can be used for drug delivery .

DSPE-PEG5000-GALA

Biochemical Assay Reagents

DSPE-PEG5000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG5000-GALA can be used for drug delivery .

HY-182098

DSPE-PEG1000-GALA	Biochemical Assay Reagents
DSPE-PEG1000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG1000-GALA can be used for drug delivery .

DSPE-PEG1000-GALA

Biochemical Assay Reagents

DSPE-PEG1000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG1000-GALA can be used for drug delivery .

HY-182098A

DSPE-PEG2000-GALA	Biochemical Assay Reagents
DSPE-PEG2000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG2000-GALA can be used for drug delivery .

DSPE-PEG2000-GALA

Biochemical Assay Reagents

DSPE-PEG2000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG2000-GALA can be used for drug delivery .

HY-182098B

DSPE-PEG3400-GALA	Biochemical Assay Reagents
DSPE-PEG3400-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG3400-GALA can be used for drug delivery .

DSPE-PEG3400-GALA

Biochemical Assay Reagents

DSPE-PEG3400-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG3400-GALA can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P5423

GALA	Exosomes Liposome	Cancer
GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. GALA significantly promotes the cytosolic release of cargos carried by exosomes, plasmids and liposomes, effectively enhances gene transfection efficiency, and drives gene knockdown of functional macromolecules (such as siRNA) in alveolar epithelial cells (with no significant cytotoxicity at effective concentrations). GALA serves as a critical tool for studies on lung cancer metastasis (e.g., melanoma lung metastasis) and lung-targeted drug delivery systems .

HY-P0311

LAH4	Bacterial	Infection
LAH4, an alpha-helix of the designed amphipathic peptide antibiotic, exhibits potent antimicrobial, nucleic acid transfection and cell penetration activities. LAH4 possesses high plasmid DNA delivery capacities. LAH4 has a strong affinity for anionic lipids found in the outer membrane of bacterial membranes .

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	DNA/RNA Synthesis	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .

HY-P0311A

LAH4 TFA	Bacterial	Infection
LAH4 TFA, an alpha-helix of the designed amphipathic peptide antibiotic, exhibits potent antimicrobial, nucleic acid transfection and cell penetration activities. LAH4 TFA possesses high plasmid DNA delivery capacities. LAH4 TFA has a strong affinity for anionic lipids found in the outer membrane of bacterial membranes .

HY-W006886

Fmoc-(R)-2-(7-octenyl)Ala-OH	Amino Acid Derivatives	Others
Fmoc-(R)-2-(7-octenyl) Ala-OH is an unnatural Fmoc-protected amino acid and modification module. Fmoc-(R)-2-(7-octenyl) Ala-OH serves as a key building block for all-hydrocarbon cross-linking modification of antimicrobial peptides, and facilitates the generation of stapled peptide derivatives. When introduced into specific sites of the parent peptide, Fmoc-(R)-2-(7-octenyl) Ala-OH effectively increases the *α-helix* content of the peptide chain, thereby significantly enhancing its antimicrobial activity and proteolytic stability. Fmoc-(R)-2-(7-octenyl) Ala-OH is widely used in research on bacterial infections and the development of related antimicrobial agents . Stapled peptide is a specially chemically modified polypeptide. It locks the peptide chain into a stable α-helical structure by introducing a "staple"-like chemical bridge (usually an all-carbon backbone) at specific positions of the peptide chain.

HY-P1341

OXA(17-33) Orexin A (17-33) (human, mouse, rat, bovine)	Orexin Receptor (OX Receptor) Sigma Receptor Phospholipase	Neurological Disease
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC₅₀=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca ²⁺ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .

HY-P4118

EB1 peptide Penetrating analog	Amino Acid Derivatives Peptide-Drug Conjugates (PDCs)	Others
EB1 peptide (Penetrating analog) is an endosomolytic agent and siRNA delivery agent. EB1 peptide forms an amphipathic alpha helix upon protonation in early-late endosomes, drives endosomal membrane permeabilization, and enables endocytosed siRNA escape into the cytosol. EB1 peptide facilitates biologically active siRNA cellular uptake and targeted gene silencing. EB1 peptide forms complexes with siRNA. EB1 peptide can be used for drug delivery research .

HY-P5959

*PTBP1 α3-helix* derived peptide P1 TFA**	Peptides	Others
PTBP1α3-helix derived peptide P1 is a polypeptide that inhibits RNA binding .

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

HY-P5917A

Vm24-toxin TFA Vaejovis mexicanus peptide 24 TFA	Potassium Channel	Inflammation/Immunology Cancer
Vm24-toxin (Vaejovis mexicanus peptide 24) TFA, a 36-residue peptide, is a potent and selective Kv1.3 blocker with a K_d of ~3 pM in lymphocytes. Vm24-toxin TFA shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin TFA folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin TFA attenuates the CD4 ⁺ effector memory T cell response to T cell receptor (TCR) stimulation .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

HY-P3916

GVLSNVIGYLKKLGTGALNAVLKQ	Bacterial	Infection Inflammation/Immunology
GVLSNVIGYLKKLGTGALNAVLKQ is an antimicrobial peptide with 24-amino acid. GVLSNVIGYLKKLGTGALNAVLKQ can potentially form α-helix. GVLSNVIGYLKKLGTGALNAVLKQ (PGQ) has activity against Gram-negative, Gram-positive bacteria and the yeast Candida albicans .

HY-P5827

SBP1 peptide	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SBP1 peptide is a chemically synthesized 23-mer peptide fragment of the ACE2 PD α1 helix. SBP1 peptide associates with micromolar affinity to insect-derived SARS-CoV-2-RBD protein .

HY-P10534

ccβ	Prion Protein	Infection Neurological Disease
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .

HY-P5917

Vm24-toxin Vaejovis mexicanus peptide 24	Potassium Channel	Inflammation/Immunology Cancer
Vm24-toxin (Vaejovis mexicanus peptide 24), a 36-residue peptide, is a potent and selective Kv1.3 blocker with a K_d of ~3 pM in lymphocytes. Vm24-toxin shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin attenuates the CD4 ⁺ effector memory T cell response to T cell receptor (TCR) stimulation .

HY-P11240

Py-Aib6-Py	Peptides	Others
Py-Aib6-Py is a hexameric peptide composed of alpha aminoisobutyric acid. Py-Aib6-Py can exist in an alpha helix conformation .

HY-P11630

ZM-804	Bacterial	Cardiovascular Disease Infection
ZM-804 is a cationic α-helix antimicrobial peptide. ZM-804 targets bacterial cell membranes. ZM-804 demonstrates antimicrobial activity and prevents the infection of tomato plants by Pst DC3000. ZM-804 inhibits the growth of B. subtilis and E. coli (the same MICs of 41.10 μg/mL). ZM-804 exhibits low hemolytic activity .

HY-P5423C

GALA-Cys	Peptides	Others
GALA-Cys is a chemically modified GALA peptide (HY-P5423) that retains GALA functions while acquiring strong covalent conjugation capability. GALA-Cys undergoes pH-driven reversible secondary structure transition, rearranges into an amphipathic α-helix, self-oligomerizes, penetrates lipid membranes to form pores, and disrupts lipid bilayers, thereby enabling endosomal escape and cytosolic cargo delivery. GALA-Cys can be conjugated with lipid DPTE for integration into liposomes, self-assembles into a tilted monolayer on gold surfaces, and serves as a pH-responsive coating for particle surface functionalization. GALA-Cys is applicable to studies related to targeted cargo delivery .

HY-P1609

CP-69799	Renin Enteropeptidase	Cardiovascular Disease
CP-69799 is an azahomostatine-containing oligopeptide transition-state analogue inhibitor with a hog renin IC₅₀ of 6e-9 M, human plasma renin IC₅₀ of 3e-7 M and K_i of 0.310 μM, and endothiapepsin K_i of 0.27 μM. CP-69799 binds endothiapepsin’s active site cleft in extended conformation, fills S4 to S3' pockets, displaces native solvent molecules, induces domain rotation, and reduces thermal mobility of endothiapepsin’s flap and helix regions. CP-69799 acts as a transition-state analogue inhibitor of hog renin and human plasma renin. CP-69799 contains a polar lysine residue at the P2' position, with a nitrogen atom replacing the P1' Cα atom of the hydroxyethylene dipeptide isostere. CP-69799 can be used for the research of hypertension .

Host:	Mouse (3) Rabbit (9)
Reactivity:	Human (12) Rat (6) Mouse (6)
Application:	IHC-P (8) ICC/IF (7) IP (5) IHC-F (2) WB (10) FC (5) ELISA (5)
Isotype:	IgG (9)
Conjugation:	Non-conjugated (12)
Clonality:	Polyclonal (1) Monoclonal (9) Recombinant (3)
Modification:	Unmodified (10)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85711

	HIF1 alpha Antibody (YA5403) Hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS domain-containing protein 8;	IHC-P, WB	Human, Mouse, Rat
	HIF1 alpha Antibody (YA5403) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

HY-P80704

	HIF1 alpha Antibody 5+ Cited Publications HIF1A; BHLHE78; MOP1; PASD8; Hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS doma	WB, ICC/IF, ELISA	Human, Mouse, Rat
	HIF1 alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to HIF1 alpha.

HY-P85201

	HIF1 alpha Antibody (YA4893) HIF1A; BHLHE78; MOP1; PASD8; Hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS doma	WB, IHC-P, IHC-F, ICC/IF, IP, FC	Human
	HIF1 alpha Antibody (YA4893) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

HY-P85201A

	HIF1 alpha Antibody (YA4893)(PBS only) HIF1A; BHLHE78; MOP1; PASD8; Hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS doma	WB, IHC-P, IHC-F, ICC/IF, IP, FC	Human
	HIF1 alpha Antibody (YA4893) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

HY-P81153

	HIF-2 alpha Antibody (YA3517) Basic helix loop helix PAS protein MOP2; Basic-helix-loop-helix-PAS protein MOP2; bHLHe73; Class E basic helix-loop-helix protein 73; ECYT4; Endothelial PAS domain containing protein 1; Endothelial pas domain protein 1; Endothelial PAS domain-containing protein 1; EPAS 1; EPAS-1; EPAS1; EPAS1_HUMAN; HIF 1 alpha like factor; HIF-1-alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; Hypoxia inducible factor 2 alpha; Hypoxia inducible factor 2 alpha subunit; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; Member of pas superfamily 2; MOP 2; MOP2; PAS domain-containing protein 2; PASD2.	WB, IHC-P, FC	Human, Mouse, Rat
	HIF-2 alpha Antibody (YA3517) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF-2 alpha.

HY-P86384

	IKK alpha Antibody (YA6076) CHUK; IKKA; TCF16; Inhibitor of nuclear factor kappa-B kinase subunit alpha; I-kappa-B kinase alpha; IKK-A; IKK-alpha; IkBKA; IkappaB kinase; Conserved helix-loop-helix ubiquitous kinase; I-kappa-B kinase 1; IKK1; Nuclear factor NF-kappa-B	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	IKK alpha Antibody (YA6076) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IKK alpha.

HY-P85216

	IKK alpha Antibody (YA4908) CHUK; IKKA; TCF16; Inhibitor of nuclear factor kappa-B kinase subunit alpha; I-kappa-B kinase alpha; IKK-A; IKK-alpha; IkBKA; IkappaB kinase; Conserved helix-loop-helix ubiquitous kinase; I-kappa-B kinase 1; IKK1; Nuclear factor NF-kappa-B	WB, ICC/IF, FC, ELISA	Human
	IKK alpha Antibody (YA4908) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to IKK alpha.

HY-P82126

	IKK alpha/beta Antibody (YA1871) CHUK; IKKA; TCF16; Inhibitor of nuclear factor kappa-B kinase subunit alpha; I-kappa-B kinase alpha; IKK-A; IKK-alpha; IkBKA; IkappaB kinase; Conserved helix-loop-helix ubiquitous kinase; I-kappa-B kinase 1; IKK1; Nuclear factor NF-kappa-B	WB, ICC/IF, IP	Human, Mouse, Rat
	IKK alpha/beta Antibody (YA1871) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IKK alpha/beta.

HY-P86459

	IKK alpha/beta Antibody (YA6151) CHUK; IKKA; TCF16; Inhibitor of nuclear factor kappa-B kinase subunit alpha; I-kappa-B kinase alpha; IKK-A; IKK-alpha; IkBKA; IkappaB kinase; Conserved helix-loop-helix ubiquitous kinase; I-kappa-B kinase 1; IKK1; Nuclear factor NF-kappa-B	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	IKK alpha/beta Antibody (YA6151) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IKK alpha/beta.

HY-P85127

	TCF3 / E2A Antibody (YA4819) TCF3; BHLHB21; E2A; ITF1; Transcription factor E2-alpha; Class B basic helix-loop-helix protein 21; bHLHb21; Immunoglobulin enhancer-binding factor E12/E47; Immunoglobulin transcription factor 1; Kappa-E2-binding factor; Transcription facto	WB, FC, ELISA	Human
	TCF3 / E2A Antibody (YA4819) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to TCF3 / E2A.

HY-P81475

	TCF3 / E2A Antibody (YA1220) TCF3; BHLHB21, E2A, ITF1; Transcription factor E2-alpha; Class B basic helix-loop-helix protein 21 (bHLHb21); Immunoglobulin enhancer-binding factor E12/E47; Immunoglobulin transcription factor 1; Kappa-E2-binding factor; Transcription factor 3 (TCF-3); Transcription factor ITF-1	IHC-P	Human
	TCF3 / E2A Antibody (YA1220) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TCF3 / E2A.

HY-P81475A

	TCF3 / E2A Antibody (YA1220)(PBS only) TCF3; BHLHB21, E2A, ITF1; Transcription factor E2-alpha; Class B basic helix-loop-helix protein 21 (bHLHb21); Immunoglobulin enhancer-binding factor E12/E47; Immunoglobulin transcription factor 1; Kappa-E2-binding factor; Transcription factor 3 (TCF-3); Transcription factor ITF-1	IHC-P	Human
	TCF3 / E2A Antibody (YA1220) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TCF3 / E2A.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: